Introduction
Materials and methods
Phase I study
Eligibility criteria
Exclusion criteria
Dose escalation protocol
Determination of MTD
Phase II study
Chemotherapy protocol
Toxicity assessment
Assessment of chemotherapeutic response
Outcome measurements
Results
Phase I study
Phase I study | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
---|---|---|---|---|---|---|
Dose escalation levela | 0 | 0 | 0 | 1 | 1 | 1 |
Age (years) | 62 | 71 | 61 | 56 | 60 | 54 |
Disease status | Advanced | Recurrent | Advanced | Advanced | Recurrent | Advanced |
Histology | G2 endometrioid | G3 endometrioid | Serous | G2 endometrioid | G2 endometrioid | G3 endometrioid |
Previous radiotherapy | No | No | No | No | No | No |
Taxane/platinum regimen | TC | TC | TC | TEC | TEC | TC |
Response to taxane/platinum regimen | Refractory | Resistant | Refractory | Refractory | Resistant | Refractory |
DLT | No | No | No | Febrile neutropenia | No | Febrile neutropenia |
aDose escalation level | Gemcitabine (mg/m2) | Levofolinate (mg/m2) | Irinotecan (mg/m2) | 5-FU (mg/m2) |
---|---|---|---|---|
Level − 2 | 500 | 100 | 50 | 1000 |
Level − 1 | 600 | 100 | 60 | 1000 |
Level 0 | 800 | 100 | 80 | 1000 |
Level 1 | 1000 | 100 | 100 | 1000 |
Level 2 | 1200 | 100 | 120 | 1000 |
Phase II study
Patients’ characteristics
Total number of patients | 28 |
Median age (range, years) | 65 (33–76) |
Disease status | |
Advanced | 5 |
Recurrent | 23 |
Histology | |
Endometrioid | |
G1 | 1 |
G2 | 8 |
G3 | 8 |
Serous | 4 |
Clear cell | 3 |
Poorly differentiated | 1 |
Mixed | 1 |
Carcinosarcoma | 2 |
Previous radiotherapy | |
Yes | 4 |
No | 24 |
Taxane/platinum regimen | |
TC | 17 |
TEC | 7 |
TAC | 4 |
AP | 3 |
DC | 1 |
Response to taxane/platinum regimen | |
Refractory | 6 |
Resistant | 22 |
Chemotherapeutic response and patients’ survival
Chemotherapeutic response | Number of patients |
---|---|
CR | 0 |
PR | 2 |
SD | 9 |
PD | 17 |
Toxicities
n = 28 | ||||||
---|---|---|---|---|---|---|
Adverse effect
|
Grade 1
|
Grade 2
|
Grade 3
|
Grade 4
|
Grade ≧ 3
(%) | |
Hematologic toxicities | ||||||
Neutropenia | 0 | 7 | 12 | 2 | 14 (50%) | |
Febrile neutropenia | 0 | 1 | 1 | 0 | 1 (3.6%) | |
Anemia | 11 | 11 | 3 | 0 | 3 (10.7%) | |
Thrombocytopenia | 2 | 1 | 0 | 0 | 0 (0%) | |
Non-hematologic toxicities | ||||||
Creatinine | 1 | 0 | 0 | 0 | 0 (0%) | |
AST | 7 | 1 | 1 | 0 | 1 (3.6%) | |
ALT | 9 | 1 | 1 | 0 | 1 (3.6%) | |
T-Bil. | 0 | 0 | 1 | 0 | 1 (3.6%) | |
γ-GTP | 6 | 3 | 1 | 1 | 2 (7.1%) | |
ALP | 6 | 2 | 0 | 0 | 0 (0%) | |
Hypernatremia | 0 | 0 | 0 | 0 | 0 (0%) | |
Hyperkalemia | 5 | 1 | 0 | 0 | 0 (0%) | |
Hyponatremia | 12 | 0 | 0 | 0 | 0 (0%) | |
Hypokalemia | 3 | 0 | 0 | 0 | 0 (0%) | |
Fever | 4 | 0 | 0 | 0 | 0 (0 %) | |
Nausea/vomiting | 18 | 2 | 0 | 0 | 0 (0%) | |
Diarrhea | 1 | 0 | 0 | 0 | 0 (0%) | |
Peripheral neuropathy | 4 | 0 | 0 | 0 | 0 (0%) | |
Myalgia/arthralgia | 4 | 0 | 0 | 0 | 0 (0%) | |
Rash | 5 | 0 | 0 | 0 | 0 (0%) | |
Skin hyperpigmentation | 1 | 0 | - | - | - | |
Arrhythmia | 1 | 1 | 0 | 0 | 0 (0%) |